Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thymoma × lenvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 123 Carcinoma, Renal Cell 28 Parkinson Disease 4, Autosomal Dominant Lewy Body 25 Neoplasms 24 Cholangiocarcinoma 24 Endometrial Neoplasms 16 Thyroid Neoplasms 15 Liver Neoplasms 15 Melanoma 13 Biliary Tract Neoplasms 10 Stomach Neoplasms 9 Recurrence 8 Carcinoma, Non-Small-Cell Lung 8 Squamous Cell Carcinoma of Head and Neck 7 Ovarian Neoplasms 7 Neoplasm Metastasis 7 Breast Neoplasms 7 Uterine Cervical Neoplasms 5 Small Cell Lung Carcinoma 5 Triple Negative Breast Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Transitional Cell 4 Thyroid Carcinoma, Anaplastic 3 Solid Tumors 3 Pancreatic Neoplasms 3 Kidney Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Diabetes Mellitus, Insulin-Dependent, 12 3 Cirrhosis, Familial, with Pulmonary Hypertension 3 Carcinoma, Ovarian Epithelial 3

Interventions

Cyclophosphamide 6 pembrolizumab 5 Cisplatin 5 Carboplatin 5 Sunitinib 4 Paclitaxel 4 Radiotherapy 3 130-nm albumin-bound paclitaxel 3 selinexor 2 Thymectomy 2 Taxes 2 Robotic Surgical Procedures 2 Ramucirumab 2 Prednisone 2 Pemetrexed 2 Octreotide 2 N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2 Imatinib Mesylate 2 Erlotinib Hydrochloride 2 Drug Therapy 2 Doxorubicin 2 Chemoradiotherapy 2 Celecoxib 2 zimberelimab 1 regorafenib 1 olaparib 1 lenvatinib 1 fludarabine 1 epacadostat 1 entinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05832827 2023-10-23

Artemis

National Cancer Center, Japan

Phase 2 Recruiting

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡